Clinical bottom line
Acute severe iron deficiency anemia (IDA) in pediatric patients requires prompt recognition and tailored management in primary care to prevent complications and support recovery. Oral iron supplementation remains the first-line treatment for most children, with intravenous iron reserved for those with intolerance, malabsorption, or severe anemia requiring rapid correction. Close monitoring of hematologic response and adherence is essential. Current evidence supports individualized treatment plans balancing efficacy, safety, and feasibility in outpatient settings (Quick Reference Guide to Pediatric Care, 2024).
What the evidence shows
Iron deficiency anemia is the most common nutritional deficiency worldwide and a frequent cause of pediatric anemia. Severe IDA in children can present with pallor, fatigue, tachycardia, and in extreme cases, cardiac compromise. Early diagnosis and management in primary care can reduce morbidity and hospitalizations (Quick Reference Guide to Pediatric Care, 2024).
Oral iron therapy, typically ferrous sulfate at 3–6 mg/kg/day of elemental iron divided into two or three doses, is effective in replenishing iron stores and correcting anemia in most pediatric patients. Absorption is enhanced when administered on an empty stomach but may be given with food to improve tolerability (Pediatric Care Online, 2016). Treatment duration is generally 3 to 6 months to restore iron stores after hemoglobin normalization (Quick Reference Guide to Pediatric Care, 2024).
Intravenous iron formulations are indicated in cases of severe anemia with hemodynamic instability, intolerance to oral iron, malabsorption syndromes, or nonadherence. Recent formulations allow for safer and more rapid administration, though evidence in pediatrics remains limited and warrants cautious use (Iron Deficiency Anemia - Management in Different Clinical Settings, 2019).
Adjunctive measures include addressing underlying causes such as nutritional deficits, chronic blood loss, or malabsorption. Dietary counseling to increase iron-rich foods and vitamin C intake may support oral therapy. Laboratory monitoring of hemoglobin and ferritin guides treatment efficacy and duration (Quick Reference Guide to Pediatric Care, 2024).
Caveats and uncertainty
Most evidence derives from observational studies and expert consensus rather than large randomized controlled trials specifically in pediatric acute severe IDA. The optimal dosing schedule and duration of oral iron therapy remain variable, with some data suggesting alternate-day dosing may improve absorption and reduce side effects, though this is not yet standard practice (Quick Reference Guide to Pediatric Care, 2024).
Intravenous iron safety and efficacy data in children are extrapolated from adult studies and limited pediatric cohorts, highlighting the need for further pediatric-specific research. Potential adverse effects, including hypersensitivity reactions, require careful consideration and monitoring (Iron Deficiency Anemia - Management in Different Clinical Settings, 2019).
There is also uncertainty regarding the best approach to screening and follow-up intervals in primary care, especially in resource-limited settings. Individual patient factors such as comorbidities, severity of anemia, and social determinants of health may influence management decisions (Pediatric Care Online, 2016).
How this may change practice
Primary care clinicians should maintain a high index of suspicion for severe IDA in children presenting with pallor, fatigue, or failure to thrive. Prompt initiation of oral iron therapy with appropriate dosing and counseling on adherence and side effects is critical. Consideration of intravenous iron therapy should be reserved for specific clinical scenarios and ideally involve specialist consultation.
Routine laboratory monitoring should include hemoglobin and ferritin levels to assess response and guide therapy duration. Incorporating dietary and social assessments can enhance treatment success and prevent recurrence.
This evidence digest underscores the importance of individualized, evidence-informed management plans for pediatric acute severe IDA in outpatient settings, balancing efficacy, safety, and patient-centered care.